China to Review IND Filing for CStone/Impact PD-L1/PARP Combo

CStone Pharma of Suzhou and Impact Therapeutics of Nanjiing announced China's NPMA accepted their IND filing for a cancer therapy that combines CStone's PD-L1 mAb with Impact's PARP inhibitor. In 2018, CStone and Impact agreed to collaborate on global clinical trials for the combination, and the acceptance of the IND filing is the first major regulatory milestone in the collaboration. The companies plan to test the combination as a treatment for advanced solid tumors. More details.... Share this with colleagues: // //